WASHINGTON - The FDA for the first time revealed its industry-negotiated vision for the next iteration of the Prescription Drug User Fee Act (PDUFA), and as expected, costs are on the rise to fund a wide set of activities beyond the drug approval process itself. (BioWorld Today) Read More
